The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer

European Journal of Cancer

Volumn 51, Issue 17, 2015, Pages 2562-2569

  Van Soest, R J ^a   Nieuweboer, A J M ^b   De Morree E S ^a   Chitu, D ^b   Bergman, A M ^c   Goey, S H ^d   Bos, M M ^e   Van Der Meer, N ^b   Hamberg, P ^f   De Wit, R ^b   Mathijssen, R H J ^b  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c NETHERLANDS CANCER INSTITUTE   (Netherlands)

^d CPRLab   (Netherlands)

^e REINIER DE GRAAF HOSPITAL   (Netherlands)

^f SINT FRANCISCUS GASTHUIS   (Netherlands)

Author keywords

Abiraterone; Cabazitaxel; Enzalutamide; Metastatic castration resistant prostate cancer; Taxanes

Indexed keywords

ABIRATERONE; ALKALINE PHOSPHATASE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR ANTAGONIST; CABAZITAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; SERUM ALBUMIN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; DOCETAXEL; PHENYLTHIOHYDANTOIN; TAXOID;

ADULT; AGED; ARTICLE; CANCER PATIENT; CASTRATION RESISTANT PROSTATE CANCER; CROSS RESISTANCE; DRUG EFFICACY; HUMAN; MALE; METASTASIS; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DISEASE FREE SURVIVAL; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TARGETED THERAPY; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; TAXOIDS; TREATMENT OUTCOME;

EID: 84948578388     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.07.037     Document Type: Article

References (24)

1. J.S. de Bono, C.J. Logothetis, A. Molina, and et al. Abiraterone and increased survival in metastatic prostate cancer N Engl J Med 364 2011 1995 2005
2. J.S. de Bono, S. Oudard, M. Ozguroglu, and et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial Lancet 376 2010 1147 1154
3. C. Parker, S. Nilsson, D. Heinrich, and et al. Alpha emitter radium-223 and survival in metastatic prostate cancer N Engl J Med 369 2013 213 223
4. H.I. Scher, K. Fizazi, F. Saad, and et al. Increased survival with enzalutamide in prostate cancer after chemotherapy N Engl J Med 367 2012 1187 1197
5. C.J. Ryan, M.R. Smith, K. Fizazi, and et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study Lancet Oncol 16 2015 152 160
6. T.M. Beer, A.J. Armstrong, D.E. Rathkopf, and et al. Enzalutamide in metastatic prostate cancer before chemotherapy N Engl J Med 371 2014 424 433
7. E.S. Antonarakis, C. Lu, H. Wang, and et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer N Engl J Med 371 2014 1028 1038
8. D.L. Suzman, B. Luber, M.T. Schweizer, R. Nadal, and E.S. Antonarakis Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone Prostate 74 2014 1278 1285
9. J. Mezynski, C. Pezaro, D. Bianchini, and et al. Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23 2012 2943 2947
10. M.T. Schweizer, X.C. Zhou, H. Wang, and et al. The influence of prior abiraterone treatment on the clinical activity of docetaxel in men with metastatic castration-resistant prostate cancer Eur Urol 66 2014 646 652
11. J.S. de Bono, M.R. Smith, F. Saad, and et al. Response to taxane chemotherapy as first subsequent therapy after abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): post-hoc analysis of COU-AA-302 J Clin Oncol 33 2015 [Suppl. 7; abstract 184]
12. I.F. Tannock, K. Fizazi, S. Ivanov, and et al. Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial Lancet Oncol 14 2013 760 786
13. R.J. van Soest, E.S. de Morree, C.F. Kweldam, and et al. Targeting the androgen receptor confers in vivo cross-resistance between enzalutamide and docetaxel, but not cabazitaxel, in castration-resistant prostate cancer Eur Urol 67 2015 981 985
14. R.J. van Soest, M.E. van Royen, E.S. de Morree, and et al. Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer Eur J Cancer 49 2013 3821 3830
15. R. Nadal, Z. Zhang, H. Rahman, and et al. Clinical activity of enzalutamide in Docetaxel-naive and Docetaxel-pretreated patients with metastatic castration-resistant prostate cancer Prostate 74 2014 1560 1568
16. N. Al Nakouzi, S. Le Moulec, L. Albiges, and et al. Cabazitaxel remains active in patients progressing after docetaxel followed by novel androgen receptor pathway targeted therapies Eur Urol 68 2015 228 235
17. C.J. Pezaro, A.G. Omlin, A. Altavilla, and et al. Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents Eur Urol 66 2014 459 465
18. De Graan AJ, Nieuweboer A, Loos WJ, et al. Effect of budesonide on the plasma exposure of cabazitaxel (Jevtana®) in castrate resistant prostate cancer patients. ASCPT 2012, PIII-41; 2012.
19. H.I. Scher, S. Halabi, I. Tannock, and et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group J Clin Oncol 26 2008 1148 1159
20. A. Angelergues, D. Maillet, A. Flechon, and et al. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer Eur J Cancer 50 2014 1602 1609
21. S. Halabi, C.Y. Lin, E.J. Small, and et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy J Natl Cancer Inst 105 2013 1729 1737
22. O. Azarenko, G. Smiyun, J. Mah, L. Wilson, and M.A. Jordan Antiproliferative mechanism of action of the novel taxane cabazitaxel as compared with the parent compound docetaxel in MCF7 breast cancer cells Mol Cancer Ther 13 2014 2092 2103
23. R. de Leeuw, L.D. Berman-Booty, M.J. Schiewer, and et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer Clin Cancer Res 21 2015 795 807
24. S. Oudard, J.S. de Bono, M. Ozguroglu, and et al. Impact of cabazitaxel + prednisone on overall survival at 2 years and in patients with aggressive disease: post-hoc analyses of TROPIC trial Ann Oncol 2012 [23 Suppl. 9; abstract 933]